Merck"s experimental under-the-skin injection of Keytruda demonstrated comparable characteristics to the intravenous version in a Phase 3 trial, prompting plans for discussions with regulators. With the IV formulation"s U.S. patent set to expire in 2028, Merck aims to sustain revenue from its leading cancer drug, which generated nearly $22 billion in sales in 2024. The subcutaneous version could offer greater convenience and is protected by new patents, but timely approval is crucial to fend off emerging biosimilar competition.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.